Advertisement

Analytical and Bioanalytical Chemistry

, Volume 407, Issue 3, pp 883–897 | Cite as

Nontargeted SWATH acquisition for identifying 47 synthetic cannabinoid metabolites in human urine by liquid chromatography-high-resolution tandem mass spectrometry

  • Karl B. Scheidweiler
  • Michael J. Y. Jarvis
  • Marilyn A. Huestis
Research Paper
Part of the following topical collections:
  1. ABCs 13th Anniversary

Abstract

Clandestine laboratories constantly produce new synthetic cannabinoids to circumvent legislative scheduling efforts, challenging and complicating toxicological analysis. Sundstrom et al. (Anal Bioanal Chem 405(26):8463–8474, [9]) and Kronstrand et al. (Anal Bioanal Chem 406(15):3599–3609, [10]) published nontargeted liquid chromatography, high-resolution, quadrupole/time-of-flight mass spectrometric (LC-QTOF) assays with validated detection of 18 and 38 urinary synthetic cannabinoid metabolites, respectively. We developed and validated a LC-QTOF urine method for simultaneously identifying the most current 47 synthetic cannabinoid metabolites from 21 synthetic cannabinoid families (5-fluoro AB-PINACA, 5-fluoro-AKB48, 5-fluoro PB-22, AB-PINACA, ADB-PINACA, AKB48, AM2201, JWH-018, JWH-019, JWH-073, JWH-081, JWH-122, JWH-200, JWH-210, JWH-250, JWH-398, MAM2201, PB-22, RCS-4, UR-144, and XLR11). β-Glucuronidase-hydrolyzed urine was extracted with 1-mL Biotage SLE+ columns. Specimens were reconstituted in 150-μL mobile phase consisting of 80 % A (0.1 % formic acid in water) and 20 % B (0.1 % formic acid in acetonitrile). Fifty microliters was injected, and SWATH™ MS data were acquired in positive electrospray mode. The LC-QTOF instrument consisted of a Shimadzu UFLCxr system and an ABSciex 5600+ TripleTOF® mass spectrometer. Gradient chromatographic separation was achieved with a Restek Ultra Biphenyl column with a 0.5-mL/min flow rate and an overall run time of 15 min. Identification criteria included molecular ion mass error, isotopic profiles, retention time, and library fit criteria. Limits of detection were 0.25–5 μg/L (N = 10 unique fortified urine samples), except for two PB-22 metabolites with limits of 10 and 20 μg/L. Extraction efficiencies and matrix effects (N = 10) were 55–104 and −65–107 %, respectively. We present a highly useful novel LC-QTOF method for simultaneously confirming 47 synthetic cannabinoid metabolites in human urine.

Graphical Abstract

SWATH acquisition MS experiment

Keywords

Synthetic cannabinoids Urine Metabolites High-resolution mass spectrometry Nontargeted SWATH LCMSMS 

Notes

Acknowledgments

The authors would like to recognize Xiang He and David Cox’s advice during method development along with Kevin L. Klette and Thomas M. Martin for providing the anonymized authentic urine specimens from the Department of Defense drug testing program. This research was supported by the Intramural Research Program of the National Institute on Drug Abuse, National Institutes of Health.

References

  1. 1.
    Presley BCJ-VS, Logan BK (2013) Analysis of synthetic cannabinoids in botanical material: a review of analytical methods and findings. Forensic Sci Rev 25(1/2):27–46Google Scholar
  2. 2.
    De Brabanter N, Deventer K, Stove V, Van Eenoo P (2013) Synthetic cannabinoids: general considerations. P Belg Roy Acad Med 2:218–234Google Scholar
  3. 3.
    Drug Enforcement Administration, Department of Justice (2011) Schedules of controlled substances: temporary placement of three synthetic cathinones into schedule I. Fed Regist 76:11075Google Scholar
  4. 4.
    United States Congress (2012) Synthetic drug abuse prevention act of 2012. https://www.govtrack.us/congress/bills/112/s3190/text
  5. 5.
    Arntson A, Ofsa B, Lancaster D, Simon JR, McMullin M, Logan B (2013) Validation of a novel immunoassay for the detection of synthetic cannabinoids and metabolites in urine specimens. J Anal Toxicol 37:284–290CrossRefGoogle Scholar
  6. 6.
    Barnes AJ, Young S, Spinelli E, Martin TM, Klette KL, Huestis MA (2014) Evaluation of a homogenous enzyme immunoassay for the detection of synthetic cannabinoids in urine. Forensic Sci Int 241C:27–34CrossRefGoogle Scholar
  7. 7.
    Castaneto MS, Desrosiers NA, Ellefsen K, Anizan S, Martin TM, Klette KL, Huestis MA (2014) Method validation of the biochip array technology for synthetic cannabinoids detection in urine. Bioanalysis (in press)Google Scholar
  8. 8.
    Wohlfarth A, Scheidweiler KB, Chen X, Liu HF, Huestis MA (2013) Qualitative confirmation of 9 synthetic cannabinoids and 20 metabolites in human urine using LC-MS/MS and library search. Anal Chem 85(7):3730–3738CrossRefGoogle Scholar
  9. 9.
    Sundstrom M, Pelander A, Angerer V, Hutter M, Kneisel S, Ojanpera I (2013) A high-sensitivity ultra-high performance liquid chromatography/high-resolution time-of-flight mass spectrometry (UHPLC-HR-TOFMS) method for screening synthetic cannabinoids and other drugs of abuse in urine. Anal Bioanal Chem 405(26):8463–8474CrossRefGoogle Scholar
  10. 10.
    Kronstrand R, Brinkhagen L, Birath-Karlsson C, Roman M, Josefsson M (2014) LC-QTOF-MS as a superior strategy to immunoassay for the comprehensive analysis of synthetic cannabinoids in urine. Anal Bioanal Chem 406(15):3599–3609CrossRefGoogle Scholar
  11. 11.
    Guale F, Shahreza S, Walterscheid JP, Chen HH, Arndt C, Kelly AT, Mozayani A (2013) Validation of LC-TOF-MS screening for drugs, metabolites, and collateral compounds in forensic toxicology specimens. J Anal Toxicol 37(1):17–24CrossRefGoogle Scholar
  12. 12.
    Möller I, Wintermeyer A, Bender K, Jübner M, Thomas A, Krug O, Schänzer W, Thevis M (2011) Screening for the synthetic cannabinoid JWH-018 and its major metabolites in human doping controls. Drug Test Anal 3(9):609–620CrossRefGoogle Scholar
  13. 13.
    Adamowicz P, Zuba D, Sekula K (2013) Analysis of UR-144 and its pyrolysis product in blood and their metabolites in urine. Forensic Sci Int 233(1–3):320–327CrossRefGoogle Scholar
  14. 14.
    Grigoryev A, Kavanagh P, Melnik A, Savchuk S, Simonov A (2013) Gas and liquid chromatography-mass spectrometry detection of the urinary metabolites of UR-144 and its major pyrolysis product. J Anal Toxicol 37(5):265–276Google Scholar
  15. 15.
    Kavanagh P, Grigoryev A, Melnik A, Simonov A (2012) The identification of the urinary metabolites of 3-(4-methoxybenzoyl)-1-pentylindole (RCS-4), a novel cannabimimetic, by gas chromatography-mass spectrometry. J Anal Toxicol 36(5):303–311CrossRefGoogle Scholar
  16. 16.
    Grigoryev A, Savchuk S, Melnik A, Moskaleva N, Dzhurko J, Ershov M, Nosyrev A, Vedenin A, Izotov B, Zabirova I, Rozhanets V (2011) Chromatography-mass spectrometry studies on the metabolism of synthetic cannabinoids JWH-018 and JWH-073, psychoactive components of smoking mixtures. J Chromatogr B 879(15–16):1126–1136CrossRefGoogle Scholar
  17. 17.
    Wohlfarth A, Pang S, Zhu M, Gandhi AS, Scheidweiler KB, Huestis MA (2014) Metabolism of RCS-8, a synthetic cannabinoid with cyclohexyl structure, in human hepatocytes by high-resolution MS. Bioanalysis 6(9):1187–1200CrossRefGoogle Scholar
  18. 18.
    Wohlfarth A, Gandhi AS, Pang S, Zhu M, Scheidweiler KB, Huestis MA (2014) Metabolism of synthetic cannabinoids PB-22 and its 5-fluoro analog, 5 F-PB-22, by human hepatocyte incubation and high-resolution mass spectrometry. Anal Bioanal Chem 406(6):1763–1780Google Scholar
  19. 19.
    Gandhi AS, Zhu M, Pang S, Wohlfarth A, Scheidweiler KB, Liu HF, Huestis MA (2013) First characterization of AKB-48 metabolism, a novel synthetic cannabinoid, using human hepatocytes and high-resolution mass spectrometry. AAPS J 15(4):1091–1098CrossRefGoogle Scholar
  20. 20.
    Gandhi AS, Zhu M, Pang S, Wohlfarth A, Scheidweiler KB, Huestis MA (2014) Metabolite profiling of RCS-4, a novel synthetic cannabinoid designer drug, using human hepatocyte metabolism and TOF-MS. Bioanalysis 6(11):1471–1485CrossRefGoogle Scholar
  21. 21.
    Wohlfarth A, Pang S, Zhu M, Gandhi AS, Scheidweiler KB, Liu HF, Huestis MA (2013) First metabolic profile of XLR-11, a novel synthetic cannabinoid, obtained by using human hepatocytes and high-resolution mass spectrometry. Clin Chem 59(11):1638–1648CrossRefGoogle Scholar
  22. 22.
    Gandhi AS, Wohlfarth A, Zhu M, Pang S, Castaneto M, Scheidweiler KB, Huestis MA (2014) High-resolution mass spectrometric metabolite profiling of a novel synthetic designer drug, N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (STS-135), using cryopreserved human hepatocytes and assessment of metabolic stability with human liver microsomes. Drug Test Anal. doi: 10.1002/dta.1662 Google Scholar
  23. 23.
    Gambaro V, Arnoldi S, Bellucci S, Casagni E, Dell'Acqua L, Fumagalli L, Pallavicini M, Roda G, Rusconi C, Valoti E (2014) Characterization of in vitro metabolites of JWH-018, JWH-073 and their 4-methyl derivatives, markers of the abuse of these synthetic cannabinoids. J Chromatogr B 957:68–76CrossRefGoogle Scholar
  24. 24.
    De Brabanter N, Esposito S, Tudela E, Lootens L, Meuleman P, Leroux-Roels G, Deventer K, Van Eenoo P (2013) In vivo and in vitro metabolism of the synthetic cannabinoid JWH-200. Rapid Commun Mass Spectrom 27(18):2115–2126CrossRefGoogle Scholar
  25. 25.
    Sobolevsky T, Prasolov I, Rodchenkov G (2012) Detection of urinary metabolites of AM-2201 and UR-144, two novel synthetic cannabinoids. Drug Test Anal 4(10):745–753CrossRefGoogle Scholar
  26. 26.
    Chimalakonda KC, Seely KA, Bratton SM, Brents LK, Moran CL, Endres GW, James LP, Hollenberg PF, Prather PL, Radominska-Pandya A, Moran JH (2012) Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in “K2/Spice”: identification of novel cannabinoid receptor ligands. Drug Metab Dispos 40(11):2174–2184CrossRefGoogle Scholar
  27. 27.
    Grigoryev A, Melnik A, Savchuk S, Simonov A, Rozhanets V (2011) Gas and liquid chromatography–mass spectrometry studies on the metabolism of the synthetic phenylacetylindole cannabimimetic JWH-250, the psychoactive component of smoking mixtures. J Chromatogr B 879(25):2519–2526CrossRefGoogle Scholar
  28. 28.
    Jang M, Yang W, Shin I, Choi H, Chang H, Kim E (2014) Determination of AM-2201 metabolites in urine and comparison with JWH-018 abuse. Int J Legal Med 128(2):285–294CrossRefGoogle Scholar
  29. 29.
    Hutter M, Broecker S, Kneisel S, Auwärter V (2012) Identification of the major urinary metabolites in man of seven synthetic cannabinoids of the aminoalkylindole type present as adulterants in ‘herbal mixtures’ using LC-MS/MS techniques. J Mass Spectrom 47(1):54–65CrossRefGoogle Scholar
  30. 30.
    Moran CL, Le V-H, Chimalakonda KC, Smedley AL, Lackey FD, Owen SN, Kennedy PD, Endres GW, Ciske FL, Kramer JB, Kornilov AM, Bratton LD, Dobrowolski PJ, Wessinger WD, Fantegrossi WE, Prather PL, James LP, Radominska-Pandya A, Moran JH (2011) Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine. Anal Chem 83(11):4228–4236CrossRefGoogle Scholar
  31. 31.
    Matuszewski BK, Constanzer ML, Chavez-Eng CM (2003) Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem 75(13):3019–3030CrossRefGoogle Scholar
  32. 32.
    University of Michigan (2013) Monitoring the future drug press release: American teens more cautious about using synthetic drugs. http://www.monitoringthefuture.org//pressreleases/13drugpr_complete.pdf
  33. 33.
    Patton AL, Chimalakonda KC, Moran CL, McCain KR, Radominska-Pandya A, James LP, Kokes C, Moran JH (2013) K2 toxicity: fatal case of psychiatric complications following AM2201 exposure. J Forensic Sci 58(6):1676–1680CrossRefGoogle Scholar
  34. 34.
    Thornton SL, Wood C, Friesen MW, Gerona RR (2013) Synthetic cannabinoid use associated with acute kidney injury. Clin Toxicol 51:189–190CrossRefGoogle Scholar
  35. 35.
    Murphy T (2013) Acute kidney injury associated with synthetic cannabinoid use—multiple states, 2012. Morbid Mortal Wkly Rep 62(6)Google Scholar
  36. 36.
    Bhanushali GK, Jain G, Fatima H, Leisch LJ, Thornley-Brown D (2013) AKI associated with synthetic cannabinoids: a case series. Clin J Am Soc Nephrol 8(4):523–526CrossRefGoogle Scholar
  37. 37.
    Winstock AR, Barratt MJ (2013) The 12-month prevalence and nature of adverse experiences resulting in emergency medical presentations associated with the use of synthetic cannabinoid products. Hum Psychopharmacol Clin Exp 28(4):390–393CrossRefGoogle Scholar
  38. 38.
    Mir A, Obafemi A, Young A, Kane C (2011) Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics 128(6):e1622–e1627CrossRefGoogle Scholar
  39. 39.
    Seely KA, Lapoint J, Moran JH, Fattore L (2012) Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry 39(2):234–243CrossRefGoogle Scholar
  40. 40.
    Wu AH, Gerona R, Armenian P, French D, Petrie M, Lynch KL (2012) Role of liquid chromatography-high-resolution mass spectrometry (LC-HR/MS) in clinical toxicology. Clin Toxicol 50(8):733–742CrossRefGoogle Scholar
  41. 41.
    Scheidweiler KB, Huestis MA (2014) Simultaneous quantification of 20 synthetic cannabinoids and 21 metabolites, and semi-quantification of 12 alkyl hydroxy metabolites in human urine by liquid chromatography-tandem mass spectrometry. J Chromatogr A 1327:105–117CrossRefGoogle Scholar
  42. 42.
    Malik-Wolf B, Vorce S, Holler J, Bosy T (2014) Evaluation of abalone beta-glucuronidase substitution in current urine hydrolysis procedures. J Anal Toxicol 38(3):171–176CrossRefGoogle Scholar
  43. 43.
    European Monitoring Centre for Drugs and Drug Addiction (2014) European Drug Report 2014: trends and developments. http://www.emcdda.europa.eu/publications/edr/trends-developments/2014

Copyright information

© Springer-Verlag Berlin Heidelberg (outside the USA) 2014

Authors and Affiliations

  • Karl B. Scheidweiler
    • 1
  • Michael J. Y. Jarvis
    • 2
  • Marilyn A. Huestis
    • 1
  1. 1.Chemistry and Drug Metabolism, Intramural Research Program, National Institute on Drug AbuseNational Institutes of HealthBaltimoreUSA
  2. 2.AB SciexConcordCanada

Personalised recommendations